UnitedHealth Crisis: UNH Stock Down 50% a Month on 2025 Profit Warning, CEO Exit

UnitedHealth leadership shakeup and worsening financial outlook trigger a deep selloff in one of the Dow ’s key components. Leadership Turmoil and Profit Suspension Shock Investors Shares of UnitedHealth Group (UNH) crashed sharply in pre-market trading today, adding to a brutal month-long decline that has now wiped out over 50% of the stock’s value. The decline accelerated after the healthcare giant announced the resignation of CEO Andrew Witty, citing personal reasons, and a suspension of its 2025 profit forecast, leaving investors in the dark about future earnings. This double blow comes as UnitedHealth grapples with rising medical expenses, ongoing changes to Medicare Advantage reimbursements, and the unresolved shock from the late-2024 murder of Brian Thompson, the head of its health benefits division. UNH Going From $600 to $311: A Stunning Collapse in Share Value Just weeks ago, in mid-April, UNH shares were trading comfortably above $600. Since then, the stock has gone into freefall: April to mid-May: down 25% to $450 Today: down another 18% to $311, marking a staggering 50% collapse in just one month The trigger? A post-earnings update and outlook downgrade in April that reduced full-year EPS estimates from $29.50–$30.00 to $24.65–$25.15, blaming “increased care activity and Medicare funding pressures.” Dow Impact and Broader Sector Weakness As one of the most heavily weighted components in the Dow Jones Industrial Average, UnitedHealth’s implosion is dragging down the index. The Dow slipped 0.65% today, while the S&P 500 and Nasdaq managed to stay in positive territory, cushioned by strength in tech and AI-related stocks. Healthcare peers are also feeling the pressure. The sharp move in UNH has triggered broader selloffs across the health insurance sector, as rising medical utilization costs and policy uncertainties loom large. Can the Board Chairman Steady the Ship? Attention now turns to Stephen Hemsley , UnitedHealth’s former CEO (2006–2017) and current board chairman. With Witty stepping down, Hemsley may play a larger role in stabilizing leadership and restoring confidence in the company’s long-term trajectory. The company said it continues to assess conditions, but admitted that “care activity is not only accelerating—it’s now impacting more types of benefit offerings than it did in Q1, with elevated costs especially evident among new Medicare Advantage enrollees.” Whether Hemsley can guide a turnaround remains to be seen, but the coming weeks will be critical for UnitedHealth as it seeks to rebuild trust in both the market and its management.